Accrued License And Milestone Fees

No definition available.

Name:	glyc_AccruedLicenseAndMilestoneFees
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Maximum milestone payment upon achievement of specified development milestone.

+ References

No definition available.

+ Details

Name:	glyc_MaximumMilestonePaymentUponAchievementOfSpecifiedDevelopmentMilestone
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum milestone payment upon achievement of specified levels of annual net sales of licensed products.

+ References

No definition available.

+ Details

Name:	glyc_MaximumMilestonePaymentUponAchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProducts
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum milestone payment upon achievement of specified regulatory milestone.

+ References

No definition available.

+ Details

Name:	glyc_MaximumMilestonePaymentUponAchievementOfSpecifiedRegulatoryMilestone
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Non Refundable Payment Received

+ References

No definition available.

+ Details

Name:	glyc_NonRefundablePaymentReceived
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payments made on execution of milestone agreement.

+ References

No definition available.

+ Details

Name:	glyc_PaymentsMadeOnExecutionOfMilestoneAgreement
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Payments for research and development expenses, under research services agreement.

+ References

No definition available.

+ Details

Name:	glyc_PaymentsforresearchanddevelopmentExpensesUnderResearchServicesAgreement
Namespace Prefix:	glyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of obligation payable for all future milestone and royalty payments received.

+ References

No definition available.

+ Details

Name:	glyc_PercentageOfObligationPayableForAllFutureMilestoneAndRoyaltyPaymentsReceived
Namespace Prefix:	glyc_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payment recognition period.

+ References

No definition available.

+ Details

Name:	glyc_UpfrontPaymentRecognitionPeriod
Namespace Prefix:	glyc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=glyc_UniversityOfBaselAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=glyc_PfizerLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Research and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended				3 Months Ended		18 Months Ended
	Feb. 29, 2016	Jun. 30, 2015	May. 31, 2014	Oct. 31, 2011	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2013	Dec. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone license fees recorded								$ 2,000,000
Accrued liability paid for research agreement	$ 2,000,000
Research and development expenses					$ 5,518,722	$ 5,207,730
University Of Basel Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of obligations payable for all future milestone and royalty payments received with respect to rivipansel					10.00%
Milestone license fees recorded								2,000,000
Pfizer License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-refundable payment against milestone payment								$ 20,000,000
Potential milestone payments upon the achievement of specified development milestones				$ 115,000,000
Potential milestone payments upon the achievement of specified regulatory milestones				70,000,000
Potential milestone payments upon the achievement specified levels of annual net sales of licensed products				135,000,000
Payment made on execution of milestone agreement				$ 22,500,000
Period of up-front payment					1 year 6 months
Revenue		$ 20,000,000	$ 15,000,000
Pfizer License Agreement [Member] \| Up-Front Payment Arrangement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Amount received and recognized as revenue							$ 22,500,000